$MRNA

Moderna, Inc.

3
3
0

No SEC Form 4 filings for $MRNA in the last 30 days.

Med

New Ebola sub-strain jumped 'from fruit bats' to humans - as Congo records more than 200 deaths while Uganda confirms three new cases

Researchers say a new Bundibugyo Ebola sub-strain in the Democratic Republic of Congo may have transferred from wildlife to humans, with fruit bats considered a likely source but not confirmed. WHO upgraded the threat to “very high.” As of the report, 204 deaths and ~870 infections are estimated in the DRC; Uganda confirmed three new cases (five total, one death). Existing Zaire-focused vaccines may not fit; WHO and partners are preparing trials and adapting treatments.

Flagship Pioneering trades 9,263 Moderna (MRNA) shares via option exercise

Flagship Pioneering, LLC, an entity associated with Moderna director Noubar Afeyan, exercised options to acquire 9,263 Moderna (MRNA) common shares at $19.15 each and subsequently sold all of them on the open market at an average price of $46.84 per share. This transaction, reported on an SEC Form 4 filing, resulted in a net sale of 9,263 shares and leaves Afeyan and related entities with substantial indirect holdings. The options were fully vested and set to expire in August 2026.

Keudell Morrison Wealth Management Invests $1.33 Million in Merck & Co., Inc. $MRK

Keudell Morrison Wealth Management recently invested $1.33 million in Merck & Co., Inc. (NYSE:MRK), purchasing 12,657 shares in the fourth quarter. The pharmaceutical giant has shown positive operating and pipeline updates, including beating earnings estimates and promising results from oncology trials. Despite some neutral and negative sentiments from analysts, Merck maintains a "Moderate Buy" rating with an average price target of $128.18.

MRNA news & sentiment — Moderna, Inc. | alphai